Technical Analysis for MEIP - MEI Pharma, Inc.

Grade Last Price % Change Price Change
grade C 2.73 -1.80% -0.05
MEIP closed down 1.8 percent on Friday, January 18, 2019, on 58 percent of normal volume. It was able to find support at its 50 day moving average.
8 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical MEIP trend table...

Date Alert Name Type % Chg
Jan 18 50 DMA Support Bullish 0.00%
Jan 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Down 3 Days in a Row Weakness 0.00%
Jan 18 Down 4 Days in a Row Weakness 0.00%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.80%
Jan 17 Wide Bands Range Expansion -1.80%
Jan 17 Overbought Stochastic Strength -1.80%
Jan 17 Down 3 Days in a Row Weakness -1.80%

Older signals for MEIP ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.
Is MEIP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Dec 20 H.C. Wainwright debuts new biotech buy list
Dec 20 Benzinga's Top Upgrades, Downgrades For December 20, 2018
Dec 7 Small healthcare stocks shrug off broad market selling
Dec 3 Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
Dec 2 The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
Dec 2 MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting
Dec 1 MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting
Nov 30 Is MEI Pharma Inc’s (NASDAQ:MEIP) CEO Paid At A Competitive Rate?
Nov 19 Market Trends Toward New Normal in Lightbridge, MEI Pharma, Good Times Restaurants, Lilis Energy, Microbot Medical, and S&W Seed — Emerging Consolidated Expectations, Analyst Ratings
Nov 12 MEI Pharma Sees Hammer Chart Pattern: Time to Buy?
See more MEIP news...
Indicators
Indicator Value
52 Week High 5.14
52 Week Low 1.82
Average Volume 276,388
200-Day Moving Average 3.3899
50-Day Moving Average 2.6898
20-Day Moving Average 2.5525
10-Day Moving Average 2.82
Average True Range 0.2045
ADX 20.56
+DI 17.608
-DI 16.0632
Chandelier Exit (Long, 3 ATRs ) 2.3665
Chandelier Exit (Short, 3 ATRs ) 2.4335
Upper Bollinger Band 3.2266
Lower Bollinger Band 1.8784
Percent B (%b) 0.63
BandWidth 52.818805
MACD Line 0.0637
MACD Signal Line 0.0253
MACD Histogram 0.0384
Fundamentals Value
Market Cap 100.84 Million
Num Shares 36.9 Million
EPS 0.07
Price-to-Earnings (P/E) Ratio 39.00
Price-to-Sales 4.35
Price-to-Book 1.98
PEG Ratio 23.80
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.05
Resistance 3 (R3) 3.06 2.98 2.99
Resistance 2 (R2) 2.98 2.90 2.97 2.97
Resistance 1 (R1) 2.85 2.85 2.81 2.84 2.96
Pivot Point 2.77 2.77 2.75 2.76 2.77
Support 1 (S1) 2.64 2.69 2.60 2.63 2.50
Support 2 (S2) 2.56 2.64 2.55 2.49
Support 3 (S3) 2.43 2.56 2.47
Support 4 (S4) 2.42